-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 10, Junshi Bio announced that the submitted clinical trial application for JS012 injection was accepted by the Food and Drug Administration for the treatment of advanced malignant tumors, such as gastric cancer and pancreatic cancer
The active ingredient of JS012 injection is a recombinant humanized anti-Claudin 18.
Claudin protein is an important molecule that constitutes tight junctions of cells, and 27 members of this protein family have been discovered
Up to now, no similar target product at home and abroad has been approved for listing